Eculizumab for Atypical Haemolytic-Uraemic Syndrome in Japan
Author Information
Author(s): Maruyama Shoichi, Ikeda Yoichiro, Kaname Shinya, Kato Noritoshi, Matsumoto Masanori, Ishikawa Yumiko, Shimono Akihiko, Miyakawa Yoshitaka, Nangaku Masaomi, Shibagaki Yugo, Okada Hirokazu
Primary Institution: Nagoya University Graduate School of Medicine
Hypothesis
The study aims to assess the safety and effectiveness of eculizumab in adult patients with atypical haemolytic-uraemic syndrome (aHUS) in Japan.
Conclusion
Eculizumab was found to be safe with no unexpected safety signals, and renal outcomes were negatively associated with the time from the most recent TMA episode to the initiation of treatment.
Supporting Evidence
- 35.3% of patients achieved complete TMA response after treatment.
- 40.4% of patients showed haematologic normalization.
- 51.3% of patients had a significant improvement in serum creatinine levels.
- 94 serious adverse events were reported in 39 patients.
- Median treatment duration was 30 weeks.
Takeaway
This study looked at how a medicine called eculizumab helps adults with a rare kidney problem called aHUS, and it found that starting the medicine sooner is better for kidney health.
Methodology
The study evaluated serious adverse events and effectiveness endpoints in adult patients with aHUS who received eculizumab, analyzing data collected during post-marketing surveillance.
Potential Biases
Patients were enrolled based on diagnosis by attending physicians, which may introduce bias.
Limitations
Missing or underreported data, different lengths of observation periods, and loss to follow-up.
Participant Demographics
Median age was 54 years, with 54.4% female and 50% having complement gene variants.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 22.4–49.9
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website